ATE288759T1 - Verwendung von stabilisierten oligonucleotiden zur herstellung von antitumoralen arzneimitteln - Google Patents

Verwendung von stabilisierten oligonucleotiden zur herstellung von antitumoralen arzneimitteln

Info

Publication number
ATE288759T1
ATE288759T1 AT00910993T AT00910993T ATE288759T1 AT E288759 T1 ATE288759 T1 AT E288759T1 AT 00910993 T AT00910993 T AT 00910993T AT 00910993 T AT00910993 T AT 00910993T AT E288759 T1 ATE288759 T1 AT E288759T1
Authority
AT
Austria
Prior art keywords
producing anti
stabilized oligonucleotides
tumoral drugs
tumoral
drugs
Prior art date
Application number
AT00910993T
Other languages
English (en)
Inventor
Antoine Carpentier
Original Assignee
Assist Publ Hopitaux De Paris
Inst Nat Sante Rech Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Assist Publ Hopitaux De Paris, Inst Nat Sante Rech Med filed Critical Assist Publ Hopitaux De Paris
Application granted granted Critical
Publication of ATE288759T1 publication Critical patent/ATE288759T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
AT00910993T 1999-03-19 2000-03-17 Verwendung von stabilisierten oligonucleotiden zur herstellung von antitumoralen arzneimitteln ATE288759T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9903433A FR2790955B1 (fr) 1999-03-19 1999-03-19 Utilisation d'oligonucleotides stabilises comme principe actif antitumoral
PCT/FR2000/000676 WO2000056342A2 (fr) 1999-03-19 2000-03-17 Utilisation d'oligonucleotides stabilises pour la preparation d'un medicament a action antitumorale

Publications (1)

Publication Number Publication Date
ATE288759T1 true ATE288759T1 (de) 2005-02-15

Family

ID=9543401

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00910993T ATE288759T1 (de) 1999-03-19 2000-03-17 Verwendung von stabilisierten oligonucleotiden zur herstellung von antitumoralen arzneimitteln

Country Status (12)

Country Link
US (2) US7700569B1 (de)
EP (1) EP1162982B9 (de)
JP (1) JP2002539265A (de)
AT (1) ATE288759T1 (de)
AU (1) AU3300600A (de)
CA (1) CA2371990A1 (de)
DE (1) DE60018050T2 (de)
DK (1) DK1162982T3 (de)
ES (1) ES2235839T3 (de)
FR (1) FR2790955B1 (de)
PT (1) PT1162982E (de)
WO (1) WO2000056342A2 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2711670B1 (fr) * 1993-10-22 1996-01-12 Pasteur Institut Vecteur nucléotidique, composition le contenant et vaccin pour l'immunisation à l'encontre d'une hépatite.
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
DK1733735T3 (en) 1998-05-22 2017-06-19 Ottawa Hospital Res Inst Methods and products for the induction of mucosal immunity
US20030022854A1 (en) 1998-06-25 2003-01-30 Dow Steven W. Vaccines using nucleic acid-lipid complexes
ES2572834T3 (es) 1999-02-17 2016-06-02 Csl Limited Complejos inmunogénicos y métodos relacionados con los mismos
FR2790955B1 (fr) * 1999-03-19 2003-01-17 Assist Publ Hopitaux De Paris Utilisation d'oligonucleotides stabilises comme principe actif antitumoral
ES2314099T3 (es) 2001-08-17 2009-03-16 Coley Pharmaceutical Gmbh Oligonucleotidos inmunoestimulantes con motivos combinados con actividad mejorada.
US7576066B2 (en) 2002-07-03 2009-08-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7807803B2 (en) 2002-07-03 2010-10-05 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7569553B2 (en) * 2002-07-03 2009-08-04 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US20040053880A1 (en) 2002-07-03 2004-03-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7605138B2 (en) 2002-07-03 2009-10-20 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
CA2503693A1 (en) 2002-10-29 2004-05-13 Coley Pharmaceutical Group, Ltd. Use of cpg oligonucleotides in the treatment of hepatitis c virus infection
US10100316B2 (en) * 2002-11-21 2018-10-16 Archemix Llc Aptamers comprising CPG motifs
JP2006512927A (ja) 2002-12-11 2006-04-20 コーリー ファーマシューティカル グループ，インコーポレイテッド ５’ｃｐｇ核酸およびその使用方法
JP2007509040A (ja) * 2003-10-11 2007-04-12 イネックス ファーマシューティカルズ コーポレイション 先天性免疫及び抗体依存性細胞傷害を強化するための方法及び組成物
EP1649859A1 (de) * 2004-10-22 2006-04-26 Institut Gustave Roussy Pharmazeutische Zubereitung, enthaltend mindestens einen gering diffusionsfähigen Antikrebsmittel sowie ein Oligodeoxynukleotid als Immunstimulans
WO2006010838A2 (fr) * 2004-06-25 2006-02-02 Institut Gustave Roussy Produits contenant au moins un principe actif anticancereux peu diffusible et un principe actif immunostimulant
MY159370A (en) 2004-10-20 2016-12-30 Coley Pharm Group Inc Semi-soft-class immunostimulatory oligonucleotides
SG160336A1 (en) 2005-03-04 2010-04-29 Dynavax Tech Corp Vaccines comprising oligonucleotides having immunostimulatory sequences (iss) wherein the iss are conjugated to antigens and stabilized by buffer conditions and further excipients
EP3199635B1 (de) 2007-05-11 2019-02-06 Adynxx, Inc. Genexpression und schmerzen
FR2975600B1 (fr) * 2011-05-24 2013-07-05 Assist Publ Hopitaux De Paris Agents pour le traitement de tumeurs
US20130210896A1 (en) * 2011-11-09 2013-08-15 City Of Hope Immunotheraphy of Brain Tumors Using a Nanoparticle CpG Delivery System
CN104487096B (zh) 2012-05-10 2020-09-15 埃迪恩克斯股份有限公司 用于活性成分递送的配制物
AU2015301491A1 (en) 2014-08-15 2017-02-02 Adynxx, Inc. Oligonucleotide decoys for the treatment of pain
EP3452081A1 (de) 2016-05-04 2019-03-13 Transgene SA Kombinationstherapie mit cpg-tlr9-liganden
JP7334124B2 (ja) 2017-06-21 2023-08-28 トランジェーヌ 個別化ワクチン
WO2019170820A1 (en) 2018-03-07 2019-09-12 Transgene Parapoxvirus vectors
CN113453712A (zh) 2018-12-28 2021-09-28 特兰斯吉恩股份有限公司 M2缺陷型痘病毒
WO2022148736A1 (en) 2021-01-05 2022-07-14 Transgene Vectorization of muc1 t cell engager

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5734033A (en) 1988-12-22 1998-03-31 The Trustees Of The University Of Pennsylvania Antisense oligonucleotides inhibiting human bcl-2 gene expression
US6153737A (en) 1990-01-11 2000-11-28 Isis Pharmaceuticals, Inc. Derivatized oligonucleotides having improved uptake and other properties
JPH04352724A (ja) * 1990-07-27 1992-12-07 Mitsui Toatsu Chem Inc 免疫調節型治療剤
EP0468520A3 (en) * 1990-07-27 1992-07-01 Mitsui Toatsu Chemicals, Inc. Immunostimulatory remedies containing palindromic dna sequences
AU2580892A (en) 1991-09-05 1993-04-05 Isis Pharmaceuticals, Inc. Determination of oligonucleotides for therapeutics, diagnostics and research reagents
US6455689B1 (en) 1993-04-30 2002-09-24 Biognostik Gesellschaft für Biomolekulare Diagnostik mbH Antisense-oligonucleotides for transforming growth factor-β (TGF-β)
AU7345694A (en) * 1993-07-10 1995-02-06 Biognostik Gesellschaft Fur Biomolekulare Diagnostik Mbh A pharmaceutical composition comprising antisense-nucleic acid for prevention and/or treatment of neuronal injury, degeneration and cell death and for the treatment of neoplasms
US6001982A (en) 1993-07-29 1999-12-14 Isis Pharmaceuticals, Inc. Synthesis of oligonucleotides
CA2172153C (en) * 1993-09-20 2010-03-09 John C. Reed Regulation of bcl-2 gene expression
WO1995026204A1 (en) 1994-03-25 1995-10-05 Isis Pharmaceuticals, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
US5563255A (en) * 1994-05-31 1996-10-08 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of raf gene expression
US6429199B1 (en) * 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
WO1996002555A1 (en) * 1994-07-15 1996-02-01 The University Of Iowa Research Foundation Immunomodulatory oligonucleotides
US6160109A (en) 1995-10-20 2000-12-12 Isis Pharmaceuticals, Inc. Preparation of phosphorothioate and boranophosphate oligomers
US6280978B1 (en) * 1995-12-15 2001-08-28 Intronn Holdings, Llc Methods and compositions for use in spliceosome mediated RNA trans-splicing
CA2256305A1 (en) * 1996-05-22 1997-11-27 Mcgill University Specific inhibitors of dna methyltransferase enzyme
EP0855184A1 (de) * 1997-01-23 1998-07-29 Grayson B. Dr. Lipford Pharmazeutisches Präparat das ein Polynukleotid und ein Antigen enthält, insbesondere zur Impfung
US5965420A (en) * 1997-03-05 1999-10-12 Smithkline Beecham Corporation Human protein kinases hYAK3
WO1998055495A2 (en) * 1997-06-06 1998-12-10 Dynavax Technologies Corporation Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
ATE294388T1 (de) * 1997-08-29 2005-05-15 Univ California Modulatoren der cytosin-5-methyl-transferase und verfahren zu ihrer verwendung
DK1009413T3 (da) * 1997-09-05 2007-06-11 Univ California Anvendelse af immunstimulerende oligonukleotider til forebyggelse eller behandling af astma
US5874416A (en) * 1997-11-07 1999-02-23 Sheikhnejad; Gholamreza RAS antisense inhibition
US6060310A (en) * 1997-11-24 2000-05-09 The United States Of America As Represented By The Department Of Health And Human Services Transcription factor decoy and tumor growth inhibitor
US6020475A (en) 1998-02-10 2000-02-01 Isis Pharmeuticals, Inc. Process for the synthesis of oligomeric compounds
US6218371B1 (en) 1998-04-03 2001-04-17 University Of Iowa Research Foundation Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
US6562798B1 (en) * 1998-06-05 2003-05-13 Dynavax Technologies Corp. Immunostimulatory oligonucleotides with modified bases and methods of use thereof
US6166239A (en) 1998-09-04 2000-12-26 Isis Pharmaceuticals, Inc. Oligonucleotide protecting groups
AU766492B2 (en) 1998-09-18 2003-10-16 Dynavax Technologies Corporation Methods of treating IgE-associated disorders and compositions for use therein
US6069243A (en) 1998-10-06 2000-05-30 Isis Pharmaceuticals, Inc. Process for oligonucleotide synthesis
WO2000021556A1 (en) 1998-10-09 2000-04-20 Dynavax Technologies Corporation Anti hiv compositions comprising immunostimulatory polynucleotides and hiv antigens
US6169177B1 (en) 1998-11-06 2001-01-02 Isis Pharmaceuticals, Inc. Processes for the synthesis of oligomeric compounds
US6121437A (en) 1999-03-16 2000-09-19 Isis Pharmaceuticals, Inc. Phosphate and thiophosphate protecting groups
FR2790955B1 (fr) * 1999-03-19 2003-01-17 Assist Publ Hopitaux De Paris Utilisation d'oligonucleotides stabilises comme principe actif antitumoral
JP2002542015A (ja) 1999-04-19 2002-12-10 エンゲルハード・コーポレーシヨン セリアと白金族金属を含んで成る触媒組成物
JP2003519662A (ja) * 2000-01-14 2003-06-24 イントラバイオティクス ファーマシューティカルズ，インコーポレイテッド ポリエン・マクロライド誘導体並びにその製法及び使用

Also Published As

Publication number Publication date
WO2000056342A3 (fr) 2001-07-26
FR2790955B1 (fr) 2003-01-17
ES2235839T3 (es) 2005-07-16
EP1162982B9 (de) 2005-07-06
DE60018050D1 (de) 2005-03-17
JP2002539265A (ja) 2002-11-19
DK1162982T3 (da) 2005-06-13
PT1162982E (pt) 2005-05-31
US20020192184A1 (en) 2002-12-19
AU3300600A (en) 2000-10-09
US7108844B2 (en) 2006-09-19
WO2000056342A2 (fr) 2000-09-28
EP1162982B1 (de) 2005-02-09
EP1162982A2 (de) 2001-12-19
CA2371990A1 (fr) 2000-09-28
DE60018050T2 (de) 2006-02-23
US7700569B1 (en) 2010-04-20
FR2790955A1 (fr) 2000-09-22

Similar Documents

Publication Publication Date Title
DE60018050D1 (de) VERWENDUNG VON STABILISIERTEn OLIGONUCLEOTIDEn ZUR HERSTELLUNG VON ANTITUMORALen ARZNEIMITTELn
CY1111504T1 (el) Αζαδικυκλοαλκανια ως ρυθμιστες του ccr5
CY1108279T1 (el) 17α-ΑΛΚΥΛΟ-17β-ΟΞΥ-ΟΙΣΤΡΑΤΡΙΕΝΙΑ ΚΑΙ ΕΝΔΙΑΜΕΣΑ ΠΡΟΪΟΝΤΑ ΓΙΑ ΤΗΝ ΠΑΡΑΓΩΓΗ ΑΥΤΩΝ, Η ΧΡΗΣΗ ΤΩΝ 17α-ΑΛΚΥΛΟ-17β-ΟΞΥ-ΟΙΣΤΡΑΤΡΙΕΝΙΩΝ ΓΙΑ ΤΗΝ ΠΑΡΑΓΩΓΗ ΦΑΡΜΑΚΕΥΤΙΚΩΝ ΜΕΣΩΝ ΚΑΘΩΣ ΚΑΙ ΦΑΡΜΑΚΕΥΤΙΚΑ ΠΑΡΑΣΚΕΥΑΣΜΑΤΑ
DE60103453D1 (de) Verwendung von albuminstabilisiertem Paclitaxel zur Herstellung eines Arzneimittels zum Behandeln von festen Tumoren und das so erhaltene Arzneimittel
TR200001892T2 (tr) Monomer cinsi ensülin analogları ve bunların kullanımı.
DE3883985D1 (de) Ärztliches instrument und dessen herstellung.
UY27455A1 (es) Derivados n-(1,4,5,6-tetrahidro-ciclopentapirazol -3-il)- sustituidos. su obtención y uso como fármacos.
EP1445253A4 (de) 4,4-difluor-1,2,3,4-tetrahydro-5h-1-benzazepinderivate und deren salze
ATE84721T1 (de) Physiologisch wirksame produkte, verfahren zur herstellung und zusammensetzung.
ES2080549T3 (es) Medicamentos a base de derivados de polihidroximetileno, procedimiento para su preparacion y empleo.
ES2056180T3 (es) Nuevos derivados de 2'-halometiliden, 2'-eteniliden y 2'-etinil citidina.
ATE231849T1 (de) Cyclopentabenzofuran-derivate und ihre verwendung
DE69841267D1 (de) Verwendung von r-carprofen zur Vorbeugung der Alzheimerschen Krankheit
DE60015560D1 (de) Verwendung von aminosäure zur herstellung von arzneimitteln zur behandlung von insulinresistenz
HUP9904294A2 (hu) Topiramát származékok alkalmazása neuropátiás fájdalom kezelésére alkalmas gyógyszer előállítására
BR9812443A (pt) 1-2-3-4-5-6-hexahidro-2,6-metano-3-benzazocin-10-óis substituìdos, processos para sua preparação e seu emprego como medicamentos
CY1106964T1 (el) Φαρμακα που περιεχουν ν,ν’-διυποκατεστημενες ενωσεις πιπεραζινης και η χρησιμοποιηση τους
BR0211223A (pt) Derivados de 4-aminociclohexanol substituìdos
PE20030236A1 (es) Derivados de bencimidazol 1-aril-2-n,s- u o-sustituidos, obtencion de medicamentos y preparados farmaceuticos que contienen estos derivados
BR0008681A (pt) Derivados de 3-amino -3-arilpropan-1-ol, processo para sua obtenção, medicamento e seu uso
RU95114858A (ru) Новый пептидный фрагмент, обладающий биологической активностью инсулина
MXPA02002486A (es) Uso de dexrazoxano para tratar la psoriasis.
NO20032799D0 (no) Nye terapeutiske anvendelser av tienylsykloheksylamin- derivater
TH54252A3 (th) อนุพันธ์ไพราโซล ที่ถูกเข้าแทนที่ตัวใหม่
ES2163966A1 (es) Glicoconjugados constituidos por la asociacion no covalente de polisacaridos con polipetidos.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1162982

Country of ref document: EP